+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06682156

Study of Carfilzomib Treatment for Chinese Patients with Newly Diagnosed Multiple Myeloma Who Cannot Tolerate Bortezomib-Based Therapy

Led by The First Affiliated Hospital of Soochow University · Updated on 2024-11-12

50

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of carfilzomib-based treatment in Chinese patients who have newly diagnosed multiple myeloma and who switch to this therapy after experiencing intolerance to a bortezomib-based triple-drug regimen. This open-label, single-arm, prospective study is conducted in real-world clinical settings and focuses on patients who cannot continue bortezomib due to side effects. Patients will receive induction and consolidation therapy lasting 6 cycles for those who undergo transplant and 8 cycles for non-transplant recipients, followed by maintenance therapy until disease progression. The carfilzomib dosing starts with 20 mgm2 on days 1 and 2, then increases to 27 mgm2 on days 8 and 9, and 36 mgm2 on days 15 and 16 for the first cycle subsequent cycles use 36 mgm2. If intolerance to bortezomib occurs during frontline therapy, patients switch to carfilzomib-based therapy. Participants will be monitored for up to 2 years, with assessments including peripheral neuropathy outcomes, overall response rates, complete and partial response rates, minimal residual disease status, and survival rates. Safety will be closely tracked through adverse event reporting. The study aims to provide real-world data on the treatments impact and tolerability during this period.

CONDITIONS

Brief Title

Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here